|
|
|
Brain (101065)
Sponsor: MUSC (101065)
|
By Malignant Hematology on
7/2/2009 4:00 AM
|
|
|
Expanded Access Protocol for Purging Blood Stem Cells or Bone Marrow from Patients with High-Risk Neuroblastoma Prior to Autologous Transplantation Under FDA Investigational Device Exemption BB-IDE-2259
None Available
|
 |
|
|
More...
|
|
|
|
|
Leukemia (100837)
Sponsor: SWOG (S0106)
|
By Malignant Hematology on
7/2/2009 4:00 AM
|
|
|
A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 56 with Previously Untreated DeNovo Acute Myeloid Leukemia (AML)
HIPAA Authorization
Informed Consent - Intervention
Protocol
|
|
|
|
|
More...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Leukemia (101352)
Sponsor: CALGB (C10603)
|
By Malignant Hematology on
7/2/2009 4:00 AM
|
|
|
A PHASE IN RANDOMIZED, DOUBLE-BLIND STUDY OF INDUCTION (DAUNORUBICIN/CYTARABINE) AND CONSOLIDATION (HIGH-DOSE CYTARABINE) CHEMOTHERAPY + MIDOSTAURIN (PKC412) (IND # 101261) OR PLACEBO IN NEWLY DIAGNOSED PATIENTS < 60 YEARS OF AGE WITH FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML)
None Available
|
|
|
|
|
More...
|
|
|
|
Leukemia (101352)
Sponsor: CALGB (C10603)
|
By Malignant Hematology on
7/2/2009 4:00 AM
|
|
|
A PHASE IN RANDOMIZED, DOUBLE-BLIND STUDY OF INDUCTION (DAUNORUBICIN/CYTARABINE) AND CONSOLIDATION (HIGH-DOSE CYTARABINE) CHEMOTHERAPY + MIDOSTAURIN (PKC412) (IND # 101261) OR PLACEBO IN NEWLY DIAGNOSED PATIENTS < 60 YEARS OF AGE WITH FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML)
None Available
|
|
|
|
|
More...
|
|
|
|
|
|
|
|
Multiple Sites (101057)
Sponsor: Osiris Therapeutics, Inc. (280)
|
By Malignant Hematology on
7/2/2009 4:00 AM
|
|
|
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal (Ex-vivo Cultured Adult Human Nesenchymal Stem Cells) Infusion for the Treatment of Steroid-Refractory Acute GVHD
None Available
|
|
|
|
|
More...
|
|
|
|